Analysis of the Introduction in Clinical Practice of New Oral Anticoagulants in Local Health Agency BT: Translation of the Clinical Trial Data to a Local Health Care Area

The commercial release of the New Oral Anticoagulants (NOACs) has been the most significant change in anticoagulant therapy in recent years. The work aimed to evaluate the economic and health impact for the Local Health Agency Barletta-Andria-Trani (BT). Through the Regional Information System data...

Full description

Saved in:
Bibliographic Details
Main Authors: Gianluca Grimaldi (Author), Domenica Ancona (Author), Domenico Tricarico (Author), Paolo Stella (Author), Cataldo Procacci (Author), Antonio Germinario (Author), Vito Bavaro (Author), Vito Montanaro (Author), Alessandro Delle Donne (Author)
Format: Book
Published: MDPI AG, 2021-02-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_d3a50cd6432d4b6f801f7890bd1be317
042 |a dc 
100 1 0 |a Gianluca Grimaldi  |e author 
700 1 0 |a Domenica Ancona  |e author 
700 1 0 |a Domenico Tricarico  |e author 
700 1 0 |a Paolo Stella  |e author 
700 1 0 |a Cataldo Procacci  |e author 
700 1 0 |a Antonio Germinario  |e author 
700 1 0 |a Vito Bavaro  |e author 
700 1 0 |a Vito Montanaro  |e author 
700 1 0 |a Alessandro Delle Donne  |e author 
245 0 0 |a Analysis of the Introduction in Clinical Practice of New Oral Anticoagulants in Local Health Agency BT: Translation of the Clinical Trial Data to a Local Health Care Area 
260 |b MDPI AG,   |c 2021-02-01T00:00:00Z. 
500 |a 10.3390/pharmaceutics13020252 
500 |a 1999-4923 
520 |a The commercial release of the New Oral Anticoagulants (NOACs) has been the most significant change in anticoagulant therapy in recent years. The work aimed to evaluate the economic and health impact for the Local Health Agency Barletta-Andria-Trani (BT). Through the Regional Information System data about naïve patients on NOAC treatment and patients on anti-vitamin-k (VKA), treatments were extrapolated. We assessed therapeutic continuity, pharmaceutical expenditure, hospitalizations, and deaths in 2017 and 2018. Therapeutic continuity was similar in the two groups. The number and the average cost of hospitalizations for a patient treated with VKAs were almost constant, while those of patients treated with NOACs decreased. The treatment of adult-aged naïve patients with NOACs, compared to VKAs therapy, involves an increase in expenditure of about 100€ for a patient, but the reduced hospitalizations could generate, in the long term, saving for the Health System. Clinical data, according to the Real-World Data, confirmed the safety and effectiveness of these drugs. However, attention to the special population is necessary to improve the safety and effectiveness of NOACs. Innovative formulations for pediatric patients are being developed. The challenge for Health Systems is the appropriate use of available resources through health interventions with transversal competences. 
546 |a EN 
690 |a NOAC 
690 |a VKA 
690 |a real-world data 
690 |a direct health costs 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Pharmaceutics, Vol 13, Iss 2, p 252 (2021) 
787 0 |n https://www.mdpi.com/1999-4923/13/2/252 
787 0 |n https://doaj.org/toc/1999-4923 
856 4 1 |u https://doaj.org/article/d3a50cd6432d4b6f801f7890bd1be317  |z Connect to this object online.